Intervacc

Stockholm, April 10, 2024 - Intervacc AB (publ) announces that the company's 2023 Annual Report has been published today. The annual report (in Swedish) is attached and an English unaudited translation of the report is available for download on the company's website intervacc.com.

For more information please contact:  

Jonas Sohlman, CEO
E-mail: jonas.sohlman@intervacc.se
Phone: +46 (0)8 120 10 600

The information was submitted for publication, through the agency of the contact person set out above on April 10, 2024, 08.30 CET.

About Intervacc

Intervacc AB is a Swedish company within animal health developing vaccines for animals. The Company's vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company´s research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB, adviser@eminova.se, +46 (0)8–684 211 10 as Certified Adviser.

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: adviser@eminova.se, Phone: +46 (0)8 – 684 211 10